Fri, December 13, 2024
[ Fri, Dec 13th 2024 ] - CNBC
The best annuity companies of 2025
[ Fri, Dec 13th 2024 ] - MSN
Bank of America: Buy, Sell, or Hold?
Thu, December 12, 2024
Wed, December 11, 2024
[ Wed, Dec 11th 2024 ] - Forbes
6 Best Value Stocks To Buy In 2025
Tue, December 10, 2024
Mon, December 9, 2024

Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900


//stocks-investing.news-articles.net/content/202 .. er-eli-lilly-lly-over-regeneron-even-at-900.html
Published in Stocks and Investing on Wednesday, December 11th 2024 at 13:41 GMT by Insider Monkey   Print publication without navigation

  • We recently published a list of Jim Cramer's Latest Calls: Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks highlighted in Jim Cramer's latest calls.

Jim Cramer, a prominent financial commentator, has expressed a strong preference for Eli Lilly (LLY) over Regeneron Pharmaceuticals, even if Eli Lilly's stock price were to reach $900 per share. In his analysis, Cramer highlights Eli Lilly's robust pipeline and its potential in the obesity and diabetes markets, particularly with drugs like Mounjaro, which has shown promising results. He contrasts this with Regeneron, noting that while it has successful products like Eylea for eye diseases, its future growth might not match Eli Lilly's due to less diversified and less expansive upcoming treatments. Cramer's endorsement of Eli Lilly is based on its innovation, market positioning, and the significant impact its new drugs could have on its revenue and stock performance.

Read the Full Insider Monkey Article at:
[ https://www.insidermonkey.com/blog/jim-cramer-says-he-would-prefer-eli-lilly-lly-over-regeneron-even-at-900-1405891/ ]

Publication Contributing Sources